For many women, their Forties bring a new kind of skin frustration: hyperpigmentation. From sun spots to uneven patches of colour, changes in skin tone can seemingly appear out of nowhere. Research from the American Academy of Dermatology shows women are more likely than men to experience pigmentation concerns, with the average age hovering around 44.
- Women are more likely to experience hyperpigmentation than men, particularly once they hit their Forties
- Dr Sam’s latest launch – its Flawless Brightly Pro Serum – is designed specifically to combat dark spots
- Powered by 10% azelaic acid, it blends hexylresorcinol, arbutin and niacinamide to help reduce excess melanin and even skin tone
Hyperpigmentation occurs when the skin produces excess melanin (the pigment responsible for skin colour), leading to patches or spots that appear darker than the surrounding skin; their appearance will depend on skin tone and the underlying cause. And while some people are happy to embrace pigmentation, others like to correct it. Enter the latest launch making waves in beauty circles: Dr Sam's Flawless Brightly Pro Serum, a targeted formula designed to help visibly diminish discolouration.
Since it was founded in 2018, the British skincare brand has fast become a cult favourite for consumers looking for a simple, no-fuss routine that promises actual results. With various active serums, targeted to specific skin concerns, the products are loved by beauty enthusiasts because they are backed by science and thorough research.
The Flawless Brightly Pro Serum is formulated with eight active ingredients. It promises to fade the appearance of three types of existing pigmentation: UV damage, post-acne pigmentation and hormonal pigmentation. It is already being hailed as a hero product with 85% of users reporting that their dark spots were visibly reduced by 85% from using it.
Dr Sam Bunting, the brains and name behind the skincare brand, spent two years researching the best ingredients for long-lasting results. She said: “I knew I had to create a solution for the millions of people who suffer with pigmentation. A product that could be used to tackle all nine biological pathways and, at the same time, help avoid the rebound phenomenon. Flawless Brightly Pro does just that. It’s a breakthrough, single serum that supports skin through each of the key stages of pigmentation development.”
Her main focus was ensuring the product could be used on a daily basis, with 100% of users agreeing it is suitable for sensitive skin. Better yet, it also has anti-ageing properties thanks to the inclusion of bakuchiol, a plant-derived alternative to retinoids which supports healthy skin turnover without harsh exfoliation. The formula also features milk thistle, which, alongside bakuchiol, offers retinol-like anti-ageing benefits with published data suggesting collagen-stimulating effects comparable to retinol, but with significantly less irritation.
What do verified shoppers say about Dr Sam’s Flawless Brightly Pro Serum?
The serum is receiving rave reviews online, with one verified shopper say: "It's actually amazed me". A second said: “It's really refreshing to use a product where I can see results without it affecting my sensitive skin. The texture is lovely and it absorbs into the skin really quickly - so handy when you're in a rush in the morning.”
Another shopper was impressed with the lightweight texture of the product, describing how “gentle on the skin” it is. As for the results, they wrote: “I can see improvement to my hyperpigmented scarring - it gradually reduces the marks.”
The formula has even been proven to work on other areas of the body, one customer said: “I’ve had great results on my neck and chest, with a real reduction in dark spots and a better complexion.”
We hope you love the products we recommend. We may receive compensation via a service called Linkby when you click on the links in this article. We only collaborate with brands on Linkby that align with our values and develop products that our team approves of. Prices accurate and items in stock at time of publication.
